Trial Profile
n Open-Label, Phase II Dose Titration Study of ACZ885 (Human Anti-IL-1β Monoclonal Antibody) to Assess the Clinical Efficacy, Safety, Pharmacokinetics and Pharmacodynamics in Patients With NALP3 Mutations
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary)
- Indications Cryopyrin-associated periodic syndromes
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 19 Nov 2014 New trial record